The stock of Nurix Therapeutics Inc (NRIX) has seen a 4.15% increase in the past week, with a 1.39% gain in the past month, and a 32.03% flourish in the past quarter. The volatility ratio for the week is 8.48%, and the volatility levels for the past 30 days are at 7.13% for NRIX. The simple moving average for the past 20 days is 6.25% for NRIX’s stock, with a 61.08% simple moving average for the past 200 days.
Is It Worth Investing in Nurix Therapeutics Inc (NASDAQ: NRIX) Right Now?
The 36-month beta value for NRIX is also noteworthy at 2.15. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NRIX is 56.85M, and at present, short sellers hold a 12.99% of that float. The average trading volume of NRIX on June 18, 2024 was 1.06M shares.
NRIX) stock’s latest price update
The stock price of Nurix Therapeutics Inc (NASDAQ: NRIX) has jumped by 10.01 compared to previous close of 15.29. Despite this, the company has seen a gain of 4.15% in its stock price over the last five trading days. globenewswire.com reported 2024-05-28 that Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies
Analysts’ Opinion of NRIX
Many brokerage firms have already submitted their reports for NRIX stocks, with Oppenheimer repeating the rating for NRIX by listing it as a “Outperform.” The predicted price for NRIX in the upcoming period, according to Oppenheimer is $25 based on the research report published on June 26, 2023 of the previous year 2023.
Barclays, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $20. The rating they have provided for NRIX stocks is “Overweight” according to the report published on March 09th, 2023.
Oppenheimer gave a rating of “Outperform” to NRIX, setting the target price at $25 in the report published on February 28th of the previous year.
NRIX Trading at 12.95% from the 50-Day Moving Average
After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.17% of loss for the given period.
Volatility was left at 7.13%, however, over the last 30 days, the volatility rate increased by 8.48%, as shares surge +2.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.65% upper at present.
During the last 5 trading sessions, NRIX rose by +3.10%, which changed the moving average for the period of 200-days by +95.88% in comparison to the 20-day moving average, which settled at $15.85. In addition, Nurix Therapeutics Inc saw 62.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRIX starting from Ring Christine, who sale 1,864 shares at the price of $17.02 back on Jun 13 ’24. After this action, Ring Christine now owns 19,838 shares of Nurix Therapeutics Inc, valued at $31,721 using the latest closing price.
Ring Christine, the Chief Legal Officer of Nurix Therapeutics Inc, sale 1,900 shares at $17.01 during a trade that took place back on Jun 12 ’24, which means that Ring Christine is holding 19,838 shares at $32,319 based on the most recent closing price.
Stock Fundamentals for NRIX
Current profitability levels for the company are sitting at:
- -1.95 for the present operating margin
- 0.82 for the gross margin
The net margin for Nurix Therapeutics Inc stands at -1.76. The total capital return value is set at -0.7. Equity return is now at value -65.37, with -42.39 for asset returns.
Based on Nurix Therapeutics Inc (NRIX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.74. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -29.14.
Currently, EBITDA for the company is -141.41 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 12.13. The receivables turnover for the company is 101.11for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.86.
Conclusion
In summary, Nurix Therapeutics Inc (NRIX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
